Avidity Biosciences reports Q2 EPS ($1.21), consensus (96c)

Reports Q2 revenue $3.8M, consensus $1.61M. Expects that its cash, cash equivalents and marketable securities as of June 30, 2025 of $1.2B, together with the net proceeds from the at-the-market offering of $185.5M, will be sufficient to fund its operations to mid-2027″Avidity continues to deliver on its leadership in RNA therapeutics as we prepare for three potential BLA submissions in a 12-month period with strong clinical data, regulatory progress, and operational execution,” said CEO Sarah Boyce. “Our programs in FSHD, DMD44 and DM1 each made meaningful advances during the second quarter of 2025, and we are encouraged by the consistent and reproducible data across these late-stage neuromuscular programs. We are keenly aware of the challenges facing patients and families living with these conditions and are preparing for potential commercialization with great thoughtfulness and urgency. ” “Avidity continues to operate from a position of financial strength,” said CFO Mike MacLean. “Avidity’s recent topline data for del-brax continues to demonstrate the consistency of the platform. As we move quickly toward potentially three successive launches starting in 2026, we continue to make meaningful progress in building our global infrastructure.”